KRTX News and Press, Karuna Therapeutics Inc. From 04/19/23

2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the Stifel 2023 CNS Days on Wednesday, March 2...

2023-03-22 12:24:28 ET Shares of Karuna Therapeutics (NASDAQ: KRTX) were up 14% late Wednesday morning on news regarding the company's lead therapy. The clinical-stage biopharmaceutical company, which focuses on therapies affecting the central nervous system, has seen its shares r...

2023-03-22 09:44:10 ET Summary KarXT is a novel antipsychotic medication being developed by Karuna Therapeutics, focusing on M1 and M4 muscarinic receptors. It has the potential to address both positive and negative symptoms of schizophrenia with a potentially more favorable side ...

2023-03-22 02:23:42 ET Karuna Therapeutics ( NASDAQ: KRTX ) on Tuesday has priced an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33/share, for expected gross proceeds to be ~$400.0M. Offering is expected to close ...

2023-03-21 16:01:16 ET Karuna Therapeutics ( NASDAQ: KRTX ) dropped for the second straight session on Tuesday to reach a seven-month low, while Wall Street brushed off safety results in a Phase 3 readout for its schizophrenia candidate KarXT, co-developed with Zai Lab Limited (...

2023-03-21 06:49:26 ET Following a ~5% drop in the prior session despite a trial win, Karuna Therapeutics ( NASDAQ: KRTX ) shares continued to tumble in the pre-market trading Tuesday after announcing the start of a $400.0M offering of its common stock. The underwritten pu...

2023-03-20 18:27:56 ET Karuna Therapeutics ( KRTX ) on Monday said it commenced an underwritten public offering of $400.0 million of its common stock. Karuna also intends to grant the underwriters a 30-day option to purchase an additional $60.0 million of its common stock. All...

2023-03-20 07:17:23 ET Karuna Therapeutics ( NASDAQ: KRTX ) announced Monday that its lead asset KarXT co-developed with Zai Lab Limited ( NASDAQ: ZLAB ), reached the primary endpoint in a Phase 3 trial for adult patients with schizophrenia. The EMERGENT-3 trial cond...

Third positive registrational trial met its primary endpoint, with KarXT demonstrating an 8.4-point reduction in PANSS total score compared to placebo at Week 5 (p<0.0001) KarXT was generally well tolerated, with a side effect profile substantially consistent with previous trials of ...